OrbiMed Advisors TRVI Position
Active3-Fund ConvergenceOrbiMed Advisors trimmed their position in Trevi Therapeutics, Inc. (TRVI) in Q4 2025, holding $39.9M worth of shares across 3,190,700 shares.
The position was first reported in Q1 2025 and has been tracked across 4 quarterly 13F filings.
TRVI is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 14.7% of float with 12.9 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Full company profile →Short Interest
14.7%
12.9 days to cover
OrbiMed Advisors TRVI Position History
Frequently Asked Questions
Does OrbiMed Advisors own TRVI?
Yes. As of Q4 2025, OrbiMed Advisors holds 3,190,700 shares of Trevi Therapeutics, Inc. (TRVI) valued at $39.9M. This data comes from their SEC 13F filing.
How many hedge funds own TRVI?
3 specialist biotech hedge funds currently hold TRVI, including Eventide Asset Management, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy TRVI?
OrbiMed Advisors's position in TRVI was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's TRVI position increasing or decreasing?
OrbiMed Advisors trimmed their TRVI position in the most recent quarter, reducing by 117,700 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TRVICompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →